Accounting for nearly 4 billion prescriptions, generic and biosimilar medicines saved the U.S. $338 billion in 2020 alone and almost $2.4 trillion over the last decade. As more biosimilars have come to market over the last few years, the U.S. has seen $8 billion in savings in 2020. Generics account for 90% of prescriptions dispensed in the U.S., but only 18.1% of the spending and 93% of all generic prescriptions are filled for less than $20.

Viatris Support for Greater Access in Healthier Markets

Generic Savings by Therapeutic Area

Generic Savings Visualized

U.S. State Map

$338BN

Total Savings

$109.6BN

Medicare Savings

$53.8BN

Medicaid Savings

Viatris Support for Greater Access in Healthier Markets

At Viatris, we are committed to making medicines more accessible by increasing competition and finding policy solutions that ensure benefits of competition reach patients. We recognize that the price of medicines can present an access challenge for patients, particularly when health system policies do not adequately support the equitable provision of health services. We believe that the value created by universal access to appropriate, high-quality medicines, particularly in the off-patent sector, is greater than the savings achieved by cuts to health and medicines budgets.

Generic Savings by Therapeutic Area:

As generics, complex generics, and biosimilar products continue to face challenges to market entry it is essential to advance meaningful policies that will increase access to affordable medicines to help patients and the U.S. healthcare system achieve the full potential of generic and biosimilar savings.

$15.9B

Cancer

$53.2B

Diabetes

$5.6B

COPD

$13.6B

Allergies and Asthma

$4.7B

HIV/AIDS

$426.7M

Multiple Sclerosis

Generics Savings Visualized

Us  Generic and Biosimilar Impact on U.S. States

https://accessiblemeds.org/2020-Access-Savings-Report

https://www.americashealthrankings.org